Last reviewed · How we verify
NCT04906720: PAPERS
Post-Ablation Pericarditis Reduction Study
Phase 2 trial testing Colchicine in Atrial Fibrillation in 248 participants. Completed in 1 October 2022.
30 January 2022
Quick facts
| Lead sponsor | St. Vincent Cardiovascular Research Institute |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 248 |
| Start date | 20 May 2021 |
| Primary completion | 30 January 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Colchicine (COLCHICINE) — full drug profile →
Conditions studied
- Atrial Fibrillation — all drugs for Atrial Fibrillation →
- Catheter Ablation — all drugs for Catheter Ablation →
- Pericarditis — all drugs for Pericarditis →
Sponsor
St. Vincent Cardiovascular Research Institute
Who can join
18 and older, any sex, with Atrial Fibrillation or Catheter Ablation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There has not been a prospective, randomized controlled trial of colchicine to reduce post-AF ablation pericarditis in an era of newer AF ablation techniques. The hypothesis is that an empiric pre and post AF ablation treatment protocol with colchicine may reduce the incidence and symptom severity of post-AF ablation related pericarditis. Thus, the goal of this study is to 1. Identify the incidence of post-AF ablation related pericarditis in patients undergoing ablation via high power, short duration strategy (shorter total RF time, but increased stability due to steerable catheters and possible difference from resistive vs conductive heating). 2. Identify potential differences in patients undergoing PVI only versus PVI + additional ablation 3. Identify whether patients on who are already on anti-inflammatories such as ASA or statins have a lower incidence than those without 4. Determine if an empiric treatment strategy with colchicine (for 7 days post ablation) reduces the incidence of post-operative AF
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review.
Zhang FS, He QZ, Qin CH, Little PJ, et al · · 2022 · cited 98× · PMID 35046517 · DOI 10.1038/s41401-021-00835-w -
Emerging Antiarrhythmic Drugs for Atrial Fibrillation.
Saljic A, Heijman J, Dobrev D. · · 2022 · cited 38× · PMID 35456912 · DOI 10.3390/ijms23084096
Verify or expand the search:
- PubMed search for NCT04906720
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Colchicine
Trials testing the same drug.
- NCT07476625 — Efficacy and Safety of Thalidomide for Pediatric PFAPA Syndrome · NA · not yet recruiting
- NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
- NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
- NCT06578182 — The Effect of ColcHicine on the Incidence of Knee or Hip Replacements · Phase 3 · recruiting
- NCT06203977 — Inflammation REduction to Prevent cArdiovascular Injury in Renal Disease (REPAIR) · Phase 1 · recruiting
Other recruiting trials for Atrial Fibrillation
Currently open trials in the same condition.
- NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
- NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
- NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
- NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
- NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
Other St. Vincent Cardiovascular Research Institute trials
Trials by the same sponsor.
- NCT06731595 — Post-Ablation Pericarditis Reduction Study (PAPERS) · Phase 2 · completed
- NCT03635034 — Bladder Catheters During Ablation Procedures · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04906720 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by St. Vincent Cardiovascular Research Institute
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04906720.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing